Condition
Gout Flares
Total Trials
4
Recruiting
1
Active
1
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
33%
1 of 3 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
4Total
P 1 (2)
P 2 (2)
Trial Status
Completed3
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT06444867Phase 1Completed
A Study to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of LEO 158968
NCT07145229Phase 2Recruiting
Safety and Efficacy of ABP-745 in Participants With an Acute Gout Flare
NCT06258213Phase 1Completed
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral ABP-745 Administration in Healthy Volunteers
NCT01712204Phase 2CompletedPrimary
A Proof-of-Concept Study of AC-201 to Prevent Gout Flares
Showing all 4 trials